Holen Sie sich die Stockscreener-App
3.03
1.68%
0.05
Handel nachbörslich:
3.03
Schlusskurs vom Vortag:
$2.98
Offen:
$3
24-Stunden-Volumen:
403.92K
Relative Volume:
1.08
Marktkapitalisierung:
$236.72M
Einnahmen:
$351.37M
Nettoeinkommen (Verlust:
$-174.01M
KGV:
-1.4638
EPS:
-2.07
Netto-Cashflow:
$-126.94M
1W Leistung:
-0.66%
1M Leistung:
-5.61%
6M Leistung:
+4.48%
1J Leistung:
-10.88%
1-Tages-Spanne:
$2.96
$3.06
1-Wochen-Bereich:
$2.925
$3.18
52-Wochen-Spanne:
$2.455
$4.02
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Firmenname
Atea Pharmaceuticals Inc
Sektor
Branche
Telefon
857-204-8109
Adresse
225 FRANKLIN STREET, BOSTON
Vergleichen Sie AVIR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
3.03 | 232.82M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-13 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-10-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-24 | Eingeleitet | JP Morgan | Overweight |
| 2020-11-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Atea Pharmaceuticals Inc Aktie (AVIR) Neueste Nachrichten
ReAlta Life Sciences (AVIR) appoints Dr. Howard Berman as Executive Chairman - Stock Titan
Will Atea Pharmaceuticals Inc. stock beat EPS estimatesTrade Risk Report & Expert Approved Momentum Trade Ideas - newser.com
Is Atea Pharmaceuticals Inc. stock reversal real or fake2025 Winners & Losers & Technical Pattern Based Buy Signals - newser.com
Will Atea Pharmaceuticals Inc. stock outperform growth indexesJuly 2025 Action & Momentum Based Trading Ideas - newser.com
How strong is Atea Pharmaceuticals Inc. stock revenue growth2025 Historical Comparison & Growth Focused Investment Plans - newser.com
Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... By GuruFocus - Investing.com Canada
Atea Pharma (NASDAQ: AVIR) hosts Evercore fireside chat Dec. 3 at 10:00 a.m. ET - Stock Titan
Is a relief rally coming for Atea Pharmaceuticals Inc. holdersProduct Launch & High Return Trade Opportunity Guides - newser.com
How Atea Pharmaceuticals Inc. stock performs in rate cut cyclesQuarterly Earnings Summary & Reliable Intraday Trade Alerts - newser.com
Atea Pharma (AVIR) Earnings Call Transcript - AOL.com
William Blair Has Negative Outlook of AVIR FY2025 Earnings - Defense World
Atea Pharmaceuticals Inc. stock trend outlook and recovery pathMarket Growth Report & Reliable Price Action Trade Plans - newser.com
Live market analysis of Atea Pharmaceuticals Inc.CEO Change & AI Enhanced Market Trend Forecasts - newser.com
Backtesting results for Atea Pharmaceuticals Inc. trading strategiesJuly 2025 Summary & Real-Time Market Sentiment Reports - newser.com
Atea Pharmaceuticals’ Earnings Call Highlights Progress and Optimism - MSN
Key metrics from Atea Pharmaceuticals Inc.’s quarterly dataMarket Trend Report & Fast Moving Stock Trade Plans - newser.com
What Makes HDFC Mutual fund a Strong Contender in YEAREarnings Call Summaries & Fast Growing Portfolio - earlytimes.in
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2025 Earnings Call Transcript - Insider Monkey
Atea Pharmaceuticals, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:AVIR) 2025-11-14 - Seeking Alpha
Atea Pharmaceuticals Advances Antiviral Programs with New Data - TipRanks
Atea Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Atea Pharmaceuticals Q3 2025 sees EPS miss By Investing.com - Investing.com Nigeria
Earnings call transcript: Atea Pharmaceuticals Q3 2025 sees EPS miss - Investing.com
Atea Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[10-Q] Atea Pharmaceuticals, Inc. Quarterly Earnings Report | AVIR SEC FilingForm 10-Q - Stock Titan
Atea Pharmaceuticals, Inc. (AVIR) Q3 FY2025 earnings call transcript - Yahoo Finance
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Atea Pharmaceuticals : Q3 Slides November 12 2025 FINAL - MarketScreener
[8-K] Atea Pharmaceuticals, Inc. Reports Material Event | AVIR SEC FilingForm 8-K - Stock Titan
Atea (Nasdaq: AVIR) says HCV Phase 3 on track; C-BEYOND topline results mid-2026 - Stock Titan
Finanzdaten der Atea Pharmaceuticals Inc-Aktie (AVIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.53%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):